QT interval prolonging drugs: Cisapride, fluconazole, octreotide, cotrimoxazole, verapamil, Class 1A and Class 3 antiarrhythmic agents.
Drugs that may increase toxicity of erythromycin: Ketoconazole.
Drugs that may reduce erythromycin plasma concentration: Carbamazepine, theophylline.
Erythromycin may increase plasma concentrations of following drugs: Carbamazepine, digoxin, theophylline, warfarin, midazolam.
|
Adverse Reactions
|
Infantile hypertrophic pyloric stenosis (IHPS): Risk of developing IHPS following erythromycin exposure is 0.4 % (95% CI 0.3–0.5%) in those receiving erythromycin at any time and 2.6 % (95% CI 1.5–4.2%) in those receiving erythromycin in the first 14 days.16
COMMON: Nausea, vomiting and abdominal pain. The incidence of GI reactions may vary with the erythromycin salt preparation and/or dosing regimen. Diarrhoea may occur due to increased gastrointestinal motility caused by erythromycin.
LESS FREQUENT OR RARE: Pancreatitis, pyloric stenosis, ileus, pseudomembranous colitis, sensorineural hearing loss, cholestasis, acute hepatitis, hepatic failure, agranulocytosis, thrombocytopenia, haemolytic anaemia, hypothermia, hypovolaemic shock and hypotension, leukocytoclastic vasculitis, acute respiratory distress following an allergic reaction, Schonlein-Henoch syndrome, candidal esophagitis, gingival hyperplasia, contact dermatitis, fixed drug eruptions, toxic pustuloderma, toxic epidermal necrolysis, interstitial nephritis, glomerulonephritis.
|
